Variable expression of RFC1 in human leukemia cell lines resistant to antifolates

Cancer Letters

Volumn 124, Issue 2, 1998, Pages 135-142

  Kobayashi, Hiroyuki ^a   Takemura, Yuzuru ^a   Ohnuma, Takao ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Department of Medicine   (United States)

Author keywords

Antifolate; Drug resistance; Human leukemia cell lines; Reduced folate carrier

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; TRITIUM;

ARTICLE; CELL STRAIN K 562; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PHENOTYPE; PRIORITY JOURNAL; SUPPLEMENTATION;

TRITIUM;

EID: 0032570546     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00464-3     Document Type: Article

References (33)

1. Elwood P.C. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J. Biol. Chem. 264:1989;14893-14901.
2. Lacey S.W., Sanders J.M., Rothberg K.G., Anderson R.G.W., Kamen B.A. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J. Clin. Invest. 84:1989;715-720.
3. Ratnam M., Marquardt H., Duhring J.L., Freisheim J.H. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry. 28:1989;8249-8254.
4. Sadasivan E., Rothenberg S.P. The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA. J. Biol. Chem. 264:1989;5806-5811.
5. Sirotnak F.M., Moccio D.M., Kelleher L.E., Goutas L.J. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res. 41:1981;4447-4452.
6. Ohnuma T., Lo R.J., Scanlon K.J., Kamen B.A., Ohnoshi T., Wolman S.R., Holland J.F. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res. 45:1985;1815-1822.
7. Schuetz J.D., Matherly L.H., Westin E.H., Goldman I.D. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line. J. Biol. Chem. 263:1988;9840-9847.
8. Dixon K.H., Trepel J.B., Eng S.C., Cowan K.H. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. Cancer Commun. 3:1991;357-365.
9. Henderson G.B., Strauss B.P. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Res. 50:1990;1709-1714.
10. Underhill T.M., Flintoff W.P. Mutant Chinese hamster ovary cells with defective methotrexate uptake are distinguishable by reversion analysis. Somatic Cell Mol. Genet. 15:1989;49-59.
11. Westerhof G.R., Rijnboutt S., Schornagel J.H., Pinedo H.M., Peters G.J., Jansen G. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Cancer Res. 55:1995;3795-3802.
12. Ohnoshi T., Ohnuma T., Takahashi I., Scanlon K.J., Kamen B.A., Holland J.F. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res. 42:1982;1655-1660.
13. Takemura Y., Gibson W., Kimbell R., Kobayashi H., Miyachi H., Jackman A.L. Cellular pharmacokinetics of ZD1694 in cultured human leukemia cells sensitive, or made resistant, to this drug. J. Cancer Res. Clin. Oncol. 122:1996;109-117.
14. Moscow J.A., Gong M., He R., Sgagias M.K., Dixon K.H., Anzick S.L., Meltzer P.S., Cowan K.H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 55:1995;3790-3794.
15. Williams F.M.R., Flintoff W.F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem. 270:1995;2987-2992.
16. Wong S.C., Proefke S.A., Bhushan A., Matherly L.H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J. Biol. Chem. 270:1995;17468-17475.
17. Gong M., Yess J., Connolly T., Ivy S.P., Ohnuma T., Cowan K.H., Moscow J.A. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human cell line. Blood. 89:1997;2494-2499.
18. Minowada J., Ohnuma T., Moore G.E. Rosette-forming human lymphoid cell lines: I. Establishment and evidence for origin of thymus-derived lymphocytes. J. Natl. Cancer Inst. 49:1972;891-895.
19. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood. 45:1975;321-334.
20. Arkin H., Ohnuma T., Kamen B.A., Holland J.F., Vallabhajosula S. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Cancer Res. 49:1989;6556-6561.
21. Kobayashi H., Kim N., Halatsch M.E., Ohnuma T. Specificity of ribozyme designed for mutated DHFR mRNA. Biochem. Pharmacol. 47:1994;1607-1613.
22. H. Kobayashi, Y. Takemura, H. Miyachi. Molecular characterization of human acute leukaemia cells resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor. Cancer Chemother. Pharmacol., in press.
23. Kobayashi H., Takemura Y., Ohnuma T. Relationship between tumor cell density and drug concentration on the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects. Cancer Chemother. Pharmacol. 31:1992;6-10.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
25. Takemura Y., Ohnuma T., Chou T.C., Okano T., Holland J.F. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother. Pharmacol. 14:1985;206-210.
26. Sirotnak F.M. Obligate genetic expression in tumor cells of a fetal membrane property mediating 'folate' transport: biological significance and implications for improved therapy of human cancer. Cancer Res. 45:1985;3992-4800.
27. Chomczynski P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal. Biochem. 201:1992;134-139.
28. Ross J.F., Chaudhuri P.K., Ratnum M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and established cell lines. Physiologic and clinical implications. Cancer. 73:1994;2432-2443.
29. Brigle K.E., Spinella M.J., Sierra E.E., Goldman I.D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J. Biol. Chem. 270:1995;22974-22979.
30. Brigle K.E., Spinella M.J., Westin E.H., Goldman I.D. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem. Pharmacol. 47:1994;337-345.
31. 10-substituted-5,8-dideazafolates. Adv. Enzyme Regul. 31:1991;13-27.
32. Takemura Y., Kobayashi H., Miyachi H., Gibson W., Kimbell R., Jackman A.L. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs. Jpn. J. Cancer Res. 87:1996;773-780.
33. Jansen G., Westerhof G.R., Jarmuszewski M.J.A., Kathmann I., Rijksen G., Schornagel J.H. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J. Biol. Chem. 265:1990;18272-18277.